Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 14, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details specific transactions executed on September 12, 2006, by Abacus Corporate Trustees Limited, acting as trustee for the GlaxoSmithKline (US) Trust ("the GSK US Trust") on behalf of participants in the GlaxoSmithKline Share Value Plan:
- Sale of 68 Ordinary Share ADRs at a price of $55.98 per ADR.
- Transfer of 102 Ordinary Share ADRs to participants in the Share Value Plan.
Three directors (Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop) hold interests in the GSK Trust in the same capacity as other employees or former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a notification of director and connected person share transactions under Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Transaction Date: September 12, 2006.
- Transaction Price: $55.98 per ADR.
- Net Activity: The Trust sold 68 ADRs and transferred 102 ADRs to plan participants.
- Directors Involved: Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop are noted as interested parties via the Trust.
- Notification Date: The Company was advised of these transactions on September 14, 2006.